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Introduction 
Binge drinking is a pattern of behavior in which excessive amounts of alcohol are consumed in a 
short period of time. The National Institute on Alcohol Abuse and Alcoholism defines a binge 
episode as a less than 2-hour period of time when a person’s blood alcohol concentration (BAC) 
reaches at least 0.08 grams percent weight per volume. For a male, this corresponds to 5 drinks 
in a two-hour time period and 4 drinks for a female in the same time period (NIAAA, 2004). 
There are many negative health effects that stem from this sort of binge drinking behavior such 
as liver disease, high blood pressure, neurological damage, stroke, and other cardiovascular 
diseases. There are also many negative psychological effects associated with binge drinking 
including changes in mood/personality, impaired attention span, depression, anxiety, sleep 
pattern disturbances, and addiction (Perkins et al. 2002). Despite these negative consequences, 
the prevalence of adults who binge drink on a regular basis is alarmingly high. One in six US 
adults or over 38 million people binge drink at least 4 times a month (CDC, 2013). Studies have 
also shown dramatic increases in the prevalence of binge drinking behavior on college campuses 
(NIAAA, 2014). With such pressing pervasiveness, it is important to investigate the 
neurobiological mechanisms underlying the reinforcing behavior of binge alcohol consumption. 
 
Binge drinking behavior has been shown to significantly increase the likelihood of developing 
alcohol addiction. Alcohol addiction is characterized by the compulsive need to obtain alcohol, 
the inability to control consumption, as well as the development of tolerance (Mello, 1973). 
Current alcohol research focuses on the factors that cause excessive drinking as well as the 
factors that lead to the development of dependence (Weiss and Porrino, 2002). Neuronal 
mechanisms that have reinforcing effects on reward seeking have been identified and studied to 
try to understand why addiction develops and why addicts relapse. A number of studies have 
strongly implied a connection between dopamine systems and the incentivizing effects of drugs 
such as alcohol (Robinson and Berridge, 1993). Studies have demonstrated that addictive drugs 
increase dopamine neurotransmission by affecting the mesolimbic pathway (Di Chiara and 
Imperato, 1988). The mesolimbic pathway is a dopaminergic pathway that connects the ventral 
tegmental area (VTA) with the nucleus accumbens region and neurotransmission in this pathway 
facilitates reinforcement of rewarding stimuli and incentive salience. Furthermore, dysregulation 
of this reward pathway has been implicated with the development and maintenance of addiction 
(Robinson and Nestler, 2012). Studies have shown that low doses of ethanol activate and 
increase the firing of the high concentrations of dopamine containing neurons in the VTA 
(Brodie et al. 1990, Young et al. 1992). The sensitivity to low concentrations of ethanol shown 
by VTA dopaminergic neurons suggests that they are involved in the reinforcing effects of 
alcohol addiction (Gessa et al. 1985). While dysfunction within the mesolimbic pathway as a 
factor contributing to addiction is widely accepted, the underlying cause of this dysfunction is 
unclear. 
 
One candidate mechanism is inflammation. Central immune signaling and the inflammatory 
response are critical for responding to tissue damage or disturbances of homeostasis in the brain, 
however, if left unresolved, excessive inflammation can become detrimental (Lobo-Silva et al. 
2016). Innate immune cells of the CNS, namely microglia, are responsible for maintaining a 
healthy, neuroprotective amount of inflammation while preventing excessive neurodegenerative 
amounts of inflammation (Crott et al. 2016). Microglia maintain neuronal homeostasis and upon 
detection of a disturbance become activated into either cytotoxic M1 or neuroprotective M2 
polarized cells (Arimoto et al.  2007). The M1 phenotype is characterized by the production of 
proinflammatory signals. Although crucial for fighting infections, many of the factors released 
by M1 microglia are damaging to neuronal cells (Fernandes et al. 2014). The M2 phenotype is 
characterized by the production of anti-inflammatory mediators and plays a part in tissue repair 
mechanisms and the cessation of inflammation. Imbalances in M1/M2 microglial activation, 
specifically M1 polarization, have been increasingly implicated in neurological and 
neurodegenerative diseases (Tang et al. 2016).  
 
Drug-induced activation of central-immune signaling has been demonstrated to contribute to 
abusive drug behavior by enhancing the engagement of the mesolimbic reward pathway (Coller 
et al. 2012). Neuroimmunomodulators such as lipopolysaccharides (LPS) have been shown to 
lead to long-lasting activation of proinflammatory brain immune signaling as well as a prolonged 
increase in high ethanol preference (Blednov et al. 2011). This further suggests that 
neuroimmune signaling can promote ethanol ingestion and alter reward-seeking behavior. 
Cytokines are major mediators of the neuroimmune response and, therefore, may play a role in 
behavioral maladaptation within the alcohol reward/aversion system. One potential cytokine of 
interest present in this pathway is interleukin-10 (IL-10). IL-10 is an anti-inflammatory cytokine 
with wide ranging roles in immunoregulation and inflammatory responses (Moore et al. 2001). 
IL-10 is produced mainly by microglia and is one of the primary mechanisms by which immune 
cells normalize imbalances in microglial M1/M2 activation and counteract damage caused by 
excessive inflammation (Lobo-Silva et al. 2016). Specifically, IL-10 has also been demonstrated 
to limit CNS inflammation by reducing synthesis of proinflammatory cytokines, suppressing 
cytokine receptor expression, and inhibiting receptor activation (Strle et al. 2001; Ledeboer et al. 
2002; Balasingam et al. 1996). IL-10 has also been shown to limit immune responses in the brain 
by inhibiting the expression of major histocompatibility complex class II (MHC-II), halting 
antigen presentation to T-cells (Lobo-Silva et al. 2016). Additionally, IL-10 gene polymorphisms 
have been associated with alcoholism. This finding further support the hypothesis that 
proinflammatory responses are linked to increased risk of alcohol dependence (Marcos et al. 
2008). Interestingly, administration of IL-10 prior to a proinflammatory LPS injection has been 
shown to revert the binge behavioral effects of the LPS injection, demonstrating its potential as a 
therapeutic approach (Bluthe et al. 1999).  
 
The “Drinking in the dark” (DID) method utilized in this study is a procedure that induces 
alcohol-preferring strains to consume enough ethanol to reach BAC’s greater than 100 mg/dl 
(Thiele and Navarro, 2014). This method is different than common involuntary ethanol 
consumption studies in that it produces pharmacologically relevant BAC’s in a time frame that 
can be set by the investigator. Furthermore, this pattern of heavy binge drinking more closely 
resembles the human behavior attempting to be modeled, giving the DID model more face 
validity than other alcohol disorder models. Another advantage of the DID model is that the mice 
are not forced to ingest the alcohol as they are in an involuntary ethanol consumption 
experiment. The DID method takes advantage of the increased ingestion behavior that 
corresponds with the animals’ dark cycle, bypassing the need to have physical interaction 
between the experimenter and the mouse (Thiele and Navarro, 2014). This interaction, which is 
necessary for involuntary administration of ethanol, introduces confounding variables into the 
study. This would be particularly troublesome because stress and anxiety caused by these 
interactions between experimenter and mouse can independently affect addictive behavior. 
The goal of this study was to determine the effects of binge ethanol consumption on the levels of 
expression of IL-10 in the VTA of the mesolimbic pathway utilizing the DID protocol. In this 
study an immunohistochemical assessment is used to measure IL-10 expression in the VTA. A 
lack of an IL-10 anti-inflammatory immune response or a decrease in basal IL-10 levels in the 
VTA could be a possible factor intensifying the inflammation of the mesolimbic reward pathway 
that underlies the behavioral maladaptations that lead to alcoholism. 
 
Methods 
Animal Handling 
Six to eight-week-old C57BL/6J mice were obtained from the Jackson Laboratory (Bar Harbor, 
Maine). The average weight of each mouse upon arrival was between 20 – 25 grams. Prior to 
undergoing any procedures, the mice were given a week to become accustomed to their new 
environment. Mice were individually housed in an AALAC certified vivarium. The vivarium 
was kept at approximately 22°C on a 12-hour reversed light-dark cycle starting with lights off at 
8:00am. During all experiments, mice had ad-libitum food and water access. All procedures used 
herein adhered to the National Institute of Health guidelines and were approved by the 
University of North Carolina Institutional Animal Care and Use Committee.   
 
Drinking in Dark 
A 4-day DID procedure was used to model binge alcohol consumption. During the DID cycle, 
the water bottles were removed from the cages of the mice and replaced with bottles containing 
20% (v/v) ethanol or 3% sucrose solution. Coinciding with the name of the procedure, all bottles 
were put on 3 hours into the dark cycle. Mice had access to the ethanol, sucrose, or water for 2 
hours before the bottles were replaced with the homecage water bottles. On the fourth day of the 
procedure the mice have access to the ethanol for 4 hours instead of 2.  Each 4 day DID 
procedure is referred to as a “cycle.” The mice underwent either 1 or 3 DID cycles, with 3 days 
of rest in between each. After the 4-hour testing period on the final test day, blood was collected 
from the mice using capillary tubes after a small incision was made on the tail. Blood samples 
were centrifuged and the serum was used to check the blood ethanol concentration (BAC) of 
each mouse using an alcohol analyzer (Analox Instruments, Lunenberg, MA) to make sure the 
mice were accurately modeling binge consumption behavior. For each mouse, BAC’s were run 
in duplicates and averaged. 
 
Immunohistochemistry 
Upon completion of the DID procedure, the mice were anesthetically overdosed with a  0.15 mL 
intraperitoneal injection of ketamine (66.67 mg/mL) and xylazine (6.67 mg/mL) dissolved in 
0.9% saline. They were then transcardially perfused with 1.0 M Phosphate Buffered Saline (PBS, 
pH = 7.4), which was immediately followed by a perfusion of 4% paraformaldehyde diluted in 
PBS. Extracted brains were postfixed in 4% paraformaldehyde for twenty-four hours. They were 
then sectioned coronally into 40 µm slices using a Leica VT 1000S vibratome (Leica 
Microsystems, Nussloch, Germany). The brain sections were placed in a 1-in-4 series so that 
every fourth slice was used in the analysis. The slices were stored in ethylene glycol, a 
cryoprotectant, at -20˚C to preserve the tissue. 
 
For immunohistochemical analysis, slices were put through three 5 minute washes of PBS (pH = 
7.4) to rinse off the ethylene glycol. The brain slices were then soaked in 0.6% hydrogen 
peroxide for 5 minutes to quench naturally occurring endogenous peroxidases. This was 
immediately followed by another 3 rinses of PBS for 5 minutes each. Next, the slices were put in 
Standard Sodium Citrate (SSC) for 1 hour for antigen retrieval. This was followed by another 
round of three 5-minute PBS washes. The slices were then blocked from nonspecific binding 
using 4% goat block for 30 minutes (Sigma-Aldrich, Raleigh, NC). This was followed by 
another 3 five-minute PBS washes. Sections were incubated in goat IL-10 primary antibody 
(1:1000; R&D Systems; Minneapolis, MN) for 48 hours at 4˚C. Primary antibody was washed 
away using 3% rabbit serum (Sigma-Aldrich, Raleigh, NC). The sections were then incubated in 
biotinylated rabbit-anti goat secondary antibody, which was followed by avidin-biotin-
peroxidase complex (ABC elite kit, Vector Labs; Burlingame, CA). The complex was detected 
with chromagen 3,3’-diaminobenzidine tetrahydrochloride (Polysciences; Warrington, PA). 
Processed sections were mounted onto glass slides and covered with SHUR/Mount™ coverslips 
(Triangle Biomedical Sciences; Durham, NC). 
 
Image Acquisition and Analysis 
An Axio Zoom.V16 microscope (Zeiss, Oberkochen, Germany) was used to capture high 
definition images of each slide at 100x magnification. Images were coded to ensure experimenter 
blindness during analyses. The Zen Pro image processing system (Zeiss, Oberkochen, Germany) 
was used to analyze the imaged brain sections. The image-processing suite digitally measures the 
immunopositive area in the region of interest on each brain slice. First, the region of interest was 
determined using the contour drawing tool to trace out the VTA region. Then a threshold was set 
to differentiate between immune-positive pixels and the background. The program then 
determines the IL-10+ area and the total area of the highlighted brain region. The 
immunoreactivity is presented as percent area, the IL-10+ area divided by the total regional area. 
 
Statistics 
All data were analyzed using Prism (GraphPad Software, Inc.; La Jolla, CA). One-way ANOVA 
tests were conducted comparing the water and ethanol groups and the water and sucrose groups 
for the VTA region. If a significant effect of treatment was determined, post-hoc Dunnett’s 
Multiple Comparison tests were used to compare sucrose or ethanol to the control water group. 
All data were reported as the mean ± standard error of the mean and analyses were considered 
significantly different if p < 0.05.  
 
Results 
Binge Alcohol Exposure Did Not Induce IL-10 Immunoreactivity in the VTA 
Central immune signaling and the release of proinflammatory cytokines in the mesolimbic 
pathway has been shown to contribute to alcohol abuse and addiction. IL-10, a potent anti-
inflammatory immunoregulator, has been shown to limit inflammation in the brain. To determine 
the effects of binge ethanol consumption on the neuroinflammatory immune response in the 
mesolimbic reward pathway, immunohistochemical assessment was used to measure IL-10 
expression in the VTA following binge drinking behavior.  
 
For the VTA, one-way ANOVA testing showed that sucrose had no effect on the IL-10 
immunoreactivity ([F = 1.020, p = 0.3750]; Figure 1A), which was expected. Sucrose controls 
were used to demonstrate that any changes in IL-10 immunoreactivity are specific to ethanol and 
do not generalize to rewarding solutions. However, ANOVA testing also indicated that EtOH 
levels had no effect on IL-10 expression for either the 1 or 3 DID cycle groups ([F = 1.352, p = 
0.2762]; Figure 1B). These results demonstrate that IL-10 levels do not significantly change in 
response to binge alcohol consumption.   
 
   
Figure 1. IL-10 Immunoreactivity visualized 
IL-10 immunoreactivity visualized at 10x magnification in the VTA and can be seen as the dark 
spots on the tissue. IL-10 was visible in both the control and experimental group. These are 
representative images.   
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Figure 2. The effects of binge-like alcohol consumption on IL-10 immunoreactivity in the 
ventral tegmental area for water control groups, 1-DID cycle groups, and 3-DID cycle groups. 
Although the figures show trending, ANOVA testing showed no significant correlation between 
EtOH and IL-10 immunoreactivity. 
 
Treatment  
Group 
Consumption  
(g/kg/day) 
BAC  
(mg/dL) 
Ethanol 1 week 
 
4.5 ± 0.4 54.1 ± 13.3 
Ethanol 3 weeks 
 
4.6 ± 0.3 61.3 ± 16.7 
Sucrose 1 week 
 
7.8 ± 0.4   
Sucrose 3 weeks 
 
7.7 ± 0.6  
 
Table 1. Ethanol consumption and blood alcohol concentrations for both the 1-week and 3-week 
ethanol and sucrose groups. Data was collected following completion of the DID cycles. Values 
shown are averages and standard deviations of each test group. 
 
Discussion 
Proinflammatory signaling has been linked with high alcohol preference and dependence in both 
mice and humans. Repeated ethanol exposure results in persistent alterations of cytokines and 
significant increases in the magnitude and duration of proinflammatory cytokine presence in the 
brain (Coller et al. 2012). Drug-induced activation of proinflammatory central immune signaling 
has been shown to contribute to abusive behavior specifically by enhancing the engagement of 
the mesolimbic dopamine reward pathway (Gessa et al. 1985). IL-10 is a major mediator of the 
neuroimmune response to binge levels of alcohol and has been shown to play a role in 
controlling unresolved inflammation by regulating M1/M2 microglial polarization (Lobo-Silva et 
al. 2016). Administration of IL-10 prior to induced proinflammatory signaling has been shown to 
revert binge alcohol consumption behavior, however the effect of binge alcohol consumption on 
basal IL-10 immunoreactivity in the mesolimbic pathway has yet to be investigated. In order to 
determine the effects of binge ethanol consumption on the neuroinflammatory immune response 
in the mesolimbic reward pathway, immunohistochemical assessment was used to measure IL-10 
expression in the VTA following a DID procedure. 
 
After the DID cycles there was no significant increase in IL-10 immunoreactivity in the VTA. 
These results suggest that the lack of a neuroimmune anti-inflammatory response in the VTA 
could be a factor intensifying the inflammation of the mesolimbic reward pathway that underlies 
the behavioral maladaptations that lead to alcoholism.  
 
However, it is too early to make any definitive conclusions because interactions between central 
immune signaling and alcohol response are extremely complicated with many interplaying 
factors. To achieve a global understanding of the homeostatic environment of the brain, it is 
necessary to understand how localized regions come together to work as system. The scope of 
this study was limited to the VTA of the mesolimbic reward pathway. The effects of binge 
ethanol consumption on central immune signaling and alcohol abuse can further be explored by 
investigating other regions of this pathway. Immunohistochemical assessment could be 
conducted on the nucleus accumbens region which has also been shown to be implicated in 
alcohol addiction (Hyman et al. 2006). Additionally, there are many other proinflammatory and 
anti-inflammatory cytokines that are activated by alcohol exposure. Future studies could 
investigate the role of other immunoregulators such as IL-1, IL-2, IL-6, IL-8, IL-12, and IL-13 
which have all been shown to elevated in alcoholics (Gonzalez-Quintela, 2000). Understanding 
the roles each of these cytokines play and how they interact with each other can further elucidate 
the link between increased central immune signaling and alcohol dependence. 
 
Future works could more accurately model the long-term nature of human binge-drinking 
behavior by conducting the DID procedure on the mice for a longer period of time. Studies could 
have groups that undergo more than 3 DID cycles to see how prolonged binge behavior effects 
IL-10 immunoreactivity in the VTA. Previous studies have found that seven days after ethanol 
exposure, there is a significant increase in IL-10 expression levels (Marshall et al, 2013). There 
was no immediate change in IL-10 expression after ethanol consumption, similar to what was 
found in the VTA for this study. Future studies should look at other time points to see how IL-10 
immunoreactivity fluctuates over longer period of binge behavior or during a period of 
abstinence in the brain regions of interest. 
 
IL-10 is one of the most widely studied suppressive molecules, however much of this research is 
focused on IL-10 in the peripheral nervous system. Knowledge on IL-10 expression and 
regulation in the CNS is much more limited. Recent studies have shown that CNS homeostasis is 
maintained by active surveillance by the innate immune system (Lampron et al. 2013). The most 
widely studied component of the CNS innate immune system is the microglia, the macrophage of 
the brain. Upon detection of disturbances in the homeostatic environment, microglia polarize into 
either the proinflammatory M1 phenotype or the anti-inflammatory M2 phenotype. While the 
M1 phenotype is important for fighting pathogens, unregulated, non-resolving microglial 
inflammation is not neuroprotective and may lead to neurodegeneration. Imbalanced polarization 
towards the M1 phenotypes has been implicated in neurodegenerative diseases including, 
neuropathic pain, Alzheimer's and Parkinson’s (Kwilasz et al. 2015). However, studies 
pioneering IL-10 as a new therapeutic approach aimed at correcting microglial imbalances have 
been met with conflicting results. Many of these problems are thought to stem from a lack of 
bioavailability in specific locations (Lobo-Silva et al. 2016). For example, intracranial 
administration of IL-10 improved outcomes for Experimental Autoimmune Encephalomyelitis, 
an animal model of brain inflammation, however, systemic delivery of IL-10 did not. Thus, a 
deep understanding of the temporal and spatial expression of IL-10 is necessary to further 
explore its potential as a therapy. Considering IL-10’s systemic importance and the promising 
results of studies investigating its efficacy as a therapeutic approach for controlling 
neuroinflammation, this lack of knowledge impedes the development of more sophisticated and 
effective immune modulatory strategies. 
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